Allogeneic CAR-T cells may address concerns related to the quality of CAR-T products, but some other issues associated with the cell type still remain. While patients undergoing CAR-T cell therapies may experience a temporary or even durable complete remission of their cancer after receiving lympho...
8,9], some issues associated with the cell type described below have prompted researchers to look for alternatives [10]. The first issue is the high
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapydoi:10.3389/fimmu.2023.1197053KILLER cellsANTIGEN receptorsIMMUNOTHERAPYCELL receptorsHEMATOLOGIC malignanciesDNAM-1 is a major NK cell activating receptor and, together with NKG2D...
"More recently, in the solid tumor area, particularly melanoma, we have seen progress in developing effective cell-based immunotherapies, and this is the first to be FDA-approved. Whilemetastatic melanomatreatment was revolutionized with immune checkpoint therapy—the first immunotherapy for cancer—and...
We also discuss the emerging new technologies involving biomaterial-assisted CAR delivery, in situ gene editing, and combined therapies that are instructive to support the next generation of CAR-Ms, a more efficient, feasible, and accessible immunotherapy for malignancy....
An engineered organic bispecific adaptor molecule that functions as a bridge between a chimeric antigen receptor (CAR) T cell and a cancer cell can potentially overcome some of the limitations posed by CAR T-cell immunotherapy technologies, according to
In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy Introduction Currently, immunotherapy methods based on immune checkpoint inhibitors, tumor vaccines, and adoptive cell therapy (ACT) have revolutionized cancer treatment. Immunotherapy has advantages over the three conventional ther...
Currently, immunotherapy methods based on immune checkpoint inhibitors, tumor vaccines, and adoptive cell therapy (ACT) have revolutionized cancer treatment. Immunotherapy has advantages over the three conventional therapies (surgery, radiotherapy, and chemotherapy) in that it can stimulate the immune system...
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Researchers from the University of Pennsylvania's Abramson Cancer Cente...
Naturally occurring stem cells isolated from humans have been used therapeutically for decades. This has primarily involved the transplantation of primary cells such as haematopoietic and mesenchymal stem cells and, more recently, derivatives of pluripot